Payment made pursuant to previously announced collaboration and license agreement for pan-KRAS inhibitor JAB-23E73

Beijing, Shanghai, and Boston, [March 30, 2026] — Jacobio Pharma (1167.HK) today announced that it has received an upfront payment of US$100 million from AstraZeneca. The payment was made in accordance with the collaboration and license agreement between the two parties regarding JAB-23E73, announced on December 21, 2025.

JAB-23E73 is an investigational oral small-molecule pan-KRAS inhibitor, designed to target a broad population of patients with KRAS-driven tumors.

Dr. Yinxian Wang, Chairman and Co-CEO of Jacobio Pharma, commented: “The receipt of this upfront payment marks an important milestone in the advancement of our partnership. We’re excited to work closely with our partner to accelerate the global development of this program, with the goal of bringing new treatment options to patients as soon as possible. Jacobio will continue to leverage its deep expertise in oncology and KRAS-targeted drug discovery to expand the global reach of its pipeline to bring more therapeutic options to patients worldwide.”

About Jacobio Pharma
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform and xADC platform, the company’s core projects focus on the KRAS pathway and STING pathway.[GU1.1] The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s R&D centers are located in Beijing and Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and more than 10 sites across several European countries.